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MaBACKGROUND Coronary computed tomography angiography (CTA)-veriﬁed positive remodeling and low attenuation
plaques are considered morphological characteristics of high-risk plaque (HRP) and predict short-term risk of acute
coronary syndrome (ACS).
OBJECTIVES This study evaluated whether plaque characteristics by CTA predict mid-term likelihood of ACS.
METHODS The presence of HRP and signiﬁcant stenosis (SS) of $70% were evaluated in 3,158 patients undergoing
CTA. Serial CTA was performed in 449 patients, and plaque progression (PP) was evaluated. Outcomes (fatal and nonfatal
ACS) were recorded during follow-up (mean 3.9  2.4 years).
RESULTS ACS occurred in 88 (2.8%) patients: 48 (16.3%) of 294 HRP(þ) and 40 (1.4%) of 2,864 HRP() patients. ACS
was also signiﬁcantly more frequent in SS(þ) (36 of 659; 5.5%) than SS() patients (52 of 2,499; 2.1%). HRP(þ)/SS(þ)
(19%) andHRP(þ)/SS() (15%) had higher rates of ACS comparedwith no-plaque patients (0.6%). Although ACS incidence
was relatively low inHRP() patients, the cumulative number of patients with ACS developing fromHRP() lesions (n¼43)
was similar to ACS patients with HRP(þ) lesions (n¼ 45). In patients with serial CTA, PP also was an independent predictor
of ACS, with HRP (27%; p < 0.0001) and without HRP (10%) compared with HRP()/PP() patients (0.3%).
CONCLUSIONS CTA-veriﬁed HRP was an independent predictor of ACS. However, the cumulative number of ACS pa-
tients with HRP() was similar to patients with HRP(þ). Additionally, plaque progression detected by serial CTA was an
independent predictor of ACS. (J Am Coll Cardiol 2015;66:337–46) © 2015 by the American College of Cardiology
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ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome
BMI = body mass index
CABG = coronary artery bypass
graft
CAD = coronary artery disease
CI = conﬁdence interval
CTA = computed tomography
angiography
FPP = feature-positive plaque
HR = hazard ratio
HRP = high-risk plaque
IQR = interquartile range
IVUS = intravascular
ultrasound
LAP = low attenuation plaque
PCI = percutaneous coronary
intervention
PIT = pathological intimal
thickening
PP = plaque progression
PR = positive remodeling
RI = remodeling index
SAP = stable angina pectoris
SS = signiﬁcant stenosis
TCFA = thin-cap ﬁbroatheroma
ThCFA = thick-cap
ﬁbroatheroma
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338C oronary computed tomographyangiography (CTA) allows noninva-sive assessment of luminal stenosis,
as well as plaque morphology (1–4). Several
reports have conﬁrmed CTA’s diagnostic ac-
curacy for identifying signiﬁcantly obstruc-
tive disease, and the severity of such
stenosis was also predictive of major adverse
cardiac events (5–7). Additionally, lesions
predictive of major adverse cardiac events
demonstrate positive remodeling (PR) and
low attenuation plaque (LAP) (8,9). Noncal-
ciﬁed plaques with #30 Hounsﬁeld unit
(HU) densities identiﬁed by CTA correlate
closely with intravascular ultrasound
(IVUS)-veriﬁed necrotic cores in coronary
atherosclerotic plaques (2). Although the
presence of PR and LAP was associated
with the development of acute coronary
syndrome (ACS) during 2-year follow-up in
our previous study (10), the mid-term prog-
nosis on the basis of CTA ﬁndings has not
been reported. In the present study, we
extended the follow-up period to investigate
the relationship between CTA-veriﬁed
high-risk plaque (HRP) and the incidence of
ACS in mid-term follow-up. In patients
with serial CTA, the association between
plaque progression (PP) and ACS was also
evaluated.SEE PAGE 347METHODS
We enrolled 4,423 consecutive patients who under-
went CTA for suspected or known coronary artery
disease (CAD) from March 2003 to May 2011. Of these,
1,265 patients were excluded from analysis, including
604 patients who underwent coronary artery bypass
graft (CABG) surgery before CTA or scheduled CABG
on the basis of CTA ﬁndings, 590 patients lacking
1-year follow-up, 37 ACS patients post-CTA wherein
the culprit lesions could not be identiﬁed, and 34
patients where ACS occurred at restenotic lesions. All
plaques were analyzed in the remaining 3,158 pa-
tients for the study, which was performed at Fujita
Health University, Nagoya Memorial Hospital, and
Imai Outpatients Clinic; the study protocol was
approved by the Institutional Review Board and
ethics committee. Dr. Narula has been associated with
this project since 2003 and has guided the pro-
ceedings of this project with Dr. Ozaki.
Of 3,158 patients, 641 had serial CTA, of whom 192
patients were excluded from analysis because ofCABG history (n ¼ 126), a short interval between ﬁrst
CTA (CTA-1) and second CTA (CTA-2) of <30 days
(n ¼ 8), and a short available follow-up period of <30
days since CTA-2 (n ¼ 58). The serial analysis involved
the remaining 449 patients, including 80 (17.8%)
who underwent CTA-2 for occurrence/recurrence of
chest pain symptoms and 122 (49.0%) for follow-up
after percutaneous coronary intervention (PCI). The
remaining 247 patients underwent serial CTA evalua-
tion at the request of treating physicians for follow-up.
The study endpoint was deﬁned as ACS occurrence
on the basis of the third universal deﬁnition of
myocardial infarction (11) and the Canadian Cardio-
vascular Society grading of angina pectoris (12).
Brieﬂy, ACS was deﬁned as ischemic discomfort pre-
senting with elevated troponin levels and ischemic
discomfort that was Canadian Cardiovascular Society
class 3 or 4 without troponin elevation. The culprit
lesion was determined by a combination of electro-
cardiographic, echocardiographic, and invasive coro-
nary angiographic ﬁndings. There were 187 deaths
(age 70.8  8.5 years; male 79%; median follow-up 1.7
years; interquartile range [IQR]: 0.6 to 4.6 years)
during follow-up: 7 sudden deaths, 30 cardiac deaths,
and 150 noncardiac deaths. Of 30 cardiac deaths, 12
were ACS-related and 18 died from heart failure.
Because we focused on coronary artery plaque char-
acteristics of ACS, cardiac death only as a result of
ACS was included as the event in this study.
Follow-up information was obtained from hospital
chart review and supplemented by information ob-
tained via mail. However, 590 patients did not follow
up with our institution or reply to the mail. Compared
with patients with complete follow-up, the patients
lost to follow-up were younger (61.7  13.0 years vs.
65.5  11.1 years), less likely to be male (60.6% vs.
69.8%), and had less HRP (5.1% vs. 9.3%). Median
follow-up duration of event-free survivors was 1,143
days (IQR: 702 to 2,081 days). One of the 3 cardiologists
(M.S., Y.N., S.K.) blinded to CTA ﬁndings was respon-
sible for reviewing patient charts and clinical pre-
sentations as well as deﬁning the ACS culprit lesion.
CTA PROTOCOL/ANALYSIS. We used 320-slice CT
(Aquilion ONE, Toshiba Medical Systems, Otawara,
Japan) and 64-slice CT (Aquilion 64, Toshiba Medical
Systems; Brilliance CT 64-channel, Philips Healthcare,
Cleveland, Ohio); older studies were performed with
16-slice CT (Aquilion 16, Toshiba Medical Systems). In
patients without contraindications, oral metoprolol
and/or intravenous landiolol was administered before
imaging if the heart rate was>65 beats/min.Whenever
possible, 0.4 mg sublingual nitroglycerin was admin-
istered 3 to 5 min before image acquisition. Tube vol-
tagewas 120 kV or 135 kV, and themaximal tube current
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339was 300mA to 580mA depending on body weight. The
mean radiation dose of the 320-slice CT was 6.2  3.9
mSv with 245 mg I/kg of contrast medium. For the 16-
and 64-slice CT, 60 to 100 ml of contrast medium
was injected. Whole-volume image acquisition was
completed in a single breath-hold. The raw data
were reconstructed using algorithms optimized for
electrocardiographic-gated reconstruction and tran-
sferred to a computer workstation for post-processing.
CTA images were evaluated on axial, coronal,
sagittal, cross-sectional, and curved multiplanar
reformation images. Two cardiologists blinded to
the patient’s clinical information interpreted the
CTA images; S.M. reviewed every study, in addition
to review by 1 more cardiologist (including H.I.,
H. Harigaya, or H.K.). Coronary artery segments with a
diameter >2 mm were evaluated for presence of pla-
ques. Segments treated previously by PCI or by elec-
tive PCI within 3 months of the base CTA ﬁndings were
excluded from assessment. Coronary atherosclerotic
lesions were quantiﬁed for lumen diameter stenosis by
visual estimation and graded as none (no luminal
stenosis), mild (1% to 39%), moderate (40% to 69%),
severe (70% to 99%) stenosis, or occluded, as per the
guidelines of the Society of Cardiovascular Computed
Tomography (13). Luminal stenosis $70% was deﬁned
as signiﬁcant stenosis (SS). Manual inspection, in both
cross section and longitudinal reconstruction, was
used for deﬁning the coronary artery remodeling index
(RI ¼ lesion diameter/reference diameter). HRP was
deﬁned as plaque with PR (RI $1.1) and/or LAP (#30
HU), which were the high-risk characteristics resulting
in ACS as previously reported (3,10,14). On the basis
of the presence of the 2 high-risk features, LAP and PR,
the plaques were designated as 1- or 2-feature–positive
plaque (FPP) or 2-feature–negative plaques (FNP).
In addition to the presence of HRP on CTA-1 and
CTA-2, PP at CTA-2 compared with CTA-1 was evalu-
ated. PP was deﬁned as either an increase in stenosis
by at least 1 grade or an increase in the RI ratio of >1.1
between CTA-1 and CTA-2. Patients who had cardiac
events before CTA-2 were excluded from serial CTA
analysis.
STATISTICAL ANALYSIS. JMP software (version 10.0,
SAS Institute, Cary, North Carolina) was used for all
statistical analyses. Two-sided p values <0.05 were
considered statistically signiﬁcant. The Shapiro-Wilk
test was used to assess the normality of continuous
data, expressed as mean  SD for normally distrib-
uted variables, or median and IQR for nonparametric
data, and compared using the Student unpaired
t test and Wilcoxon signed rank test, respectively.
Categorical variables are presented as frequencies
(percents) and compared using the chi-square test orFisher exact test depending on the category cell size.
Kaplan-Meier survival analysis was used to estimate
the distribution of time to cardiac events according
to the presence or absence of HRP, stenosis, or PP.
Differences in time-to-event curves were compared
with the log-rank statistic. The effect of the variables
on cardiac events was evaluated using the univariable
Cox proportional hazards models. Age and other
variables with p values <0.05 in the univariable
analysis were then included in multivariable Cox
proportional hazard analysis. The proportional haz-
ards assumption was assessed with log (log [survival
rate]) versus log [survival time]) plot and with models
including interaction between covariates and survival
time. No relevant violations were observed.
Results are reported as hazard ratios (HRs) with 95%
conﬁdence intervals (CIs). The increased discrimina-
tive value after the addition of HRP and SS to the
established clinical risk factors was estimated using
the C-index for the receiver-operating characteristic
curve. The C-index is deﬁned as the area under
a receiver-operating characteristic curve between
individual predicted probabilities and incidence of
events, and is compared in a baseline model and in
an enriched model with HRP, SS, and HRP þ SS.
RESULTS
PATIENT-BASED ANALYSIS. In the 3,158 enrolled
patients (age 66  11 years, male 70%), the follow-up
was a mean of 3.9  2.4 years (range: 1 to 10.5 years;
IQR: 1.9 to 5.7 years). HRP was detected in 294 (9.3%)
patients. The HRP(þ) patients differed signiﬁcantly
from HRP() patients: they were older; more likely
male; more likely to have hypertension, dyslipidemia,
diabetes mellitus, and a history of ACS; and more
likely to be on statin therapy post-CTA (Table 1).
Of the 3,158 patients, signiﬁcant luminal sten-
osis $70% [SS(þ) group] was present in at least 1
coronary artery in 659 (21%) patients. The SS(þ) group
also differed signiﬁcantly compared to the SS() pa-
tients on the basis of older age, male sex, and the
presence of hypertension, dyslipidemia, diabetes
mellitus, current smoking, previous ACS, and statin
use after CTA (Table 1). Of the 3,158 patients, ACS
developed in 88 (2.8%) patients during follow-up
(Figure 1). The culprit lesion was found in the right
coronary artery in 40 patients, left main trunk in 4
patients, left anterior descending coronary artery in
37, and left circumﬂex coronary artery in 7 patients.
Two ACS events occurred in patients with apparently
normal coronary arteries; IVUS at the time of the
acute event demonstrated no plaque rupture, but
coronary artery spasm superimposed on minimally
FIGURE 1 Occurren
SS(+)
117
ACS 22(16+3+3)*
Acute coronary synd
or absence () of hig
SS(þ) patients, 3 AC
with HRP but withou
TABLE 1 Patient Characteristics
Total
(n ¼ 3,158)
HRP(þ)
(n ¼ 294, 9.3%)
HRP()
(n ¼ 2,864, 90.7%) p Value
Stenosis $70%
(n ¼ 659, 20.9%)
Stenosis <70%
(n ¼ 2,499, 79.1%) p Value
Age, yrs 65.5  11.1 66.9  9.3 65.3  11.2 0.0216 68.4  9.6 64.7  11.4 <0.0001
Male 2,203 (69.8) 258 (87.8) 1,945 (67.9) <0.0001 511 (77.5) 1,692 (67.7) <0.0001
Hypertension 1,752 (55.5) 199 (67.7) 1,553 (54.2) <0.0001 468 (71.0) 1,284 (51.4) <0.0001
Dyslipidemia 1,518 (48.1) 171 (58.2) 1,347 (47.0) 0.0003 373 (56.6) 1,145 (45.8) <0.0001
Diabetes 723 (22.9) 86 (29.3) 637 (22.2) 0.0064 201 (30.5) 522 (20.9) <0.0001
Current smoking 554 (17.5) 83 (28.2) 471 (16.4) <0.0001 128 (19.4) 426 (17.0) 0.0007
BMI >25 kg/m2 901 (28.5) 94 (32.0) 807 (28.2) 0.1699 201 (30.5) 700 (28.0) 0.2080
Previous ACS 852 (27.0) 145 (49.3) 707 (24.7) <0.0001 256 (38.8) 596 (23.8) <0.0001
Statin after CTA 1,227 (38.9) 168 (57.1) 1,059 (37.0) <0.0001 297 (45.1) 930 (37.2) 0.0002
Values are mean  SD or n (%).
ACS ¼ acute coronary syndrome; BMI ¼ body mass index; CTA ¼ computed tomography angiography; HRP ¼ high-risk plaque.
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340occlusive plaques was documented during coronary
angiography. Multivariable Cox hazard analysis
showed that dyslipidemia, body mass index (BMI)
>25 kg/m2, previous ACS, HRP, and SS were inde-
pendent predictors of developing ACS (Table 2).
Patients with high-risk features on CTA developed
ACS at a signiﬁcantly higher rate; ACS occurred in 31
of 135 (23.0%) patients with 2-FPP, 17 of 159 (10.7%)
patients with 1-FPP, 38 of 2,504 (1.6%) patients with
2-FNP, and 2 of 360 (0.6%) patients without any pla-
que (log-rank p < 0.0001) (Figure 2A). The SS group
had a higher rate of developing ACS than SS() patients
(36 of 659 [5.5%] vs. 52 of 2,499 [2.1%]; log-rank
p < 0.0001) (Figure 2B). Patients were classiﬁed into
5 groups on the basis of HRP and SS [HRP(þ)/SS(þ),ce of ACS on the Basis of Plaque and Stenosis
Total
3,158
HRP(-)
2,864
HRP(+)
294
SS(-)
2322
SS(+)
542
SS(-)
177
26 14
(13+1)†
26
rome (ACS) occurred in a number of patients shown with presence (þ)
h-risk plaque (HRP) or signiﬁcant stenosis (SS) of $70%. *In HRP(þ)/
S occurred at the SS but accompanying non-HRP and 3 at the lesions
t SS. †In HRP()/SS(þ) patients, 1 ACS occurred at SS() lesion.HRP(þ)/SS(), HRP()/SS(þ), HRP()/SS(), and no
plaque], with event rates of 18.8%, 14.9%, 2.6%, 1.2%,
and 0.6%, respectively. Kaplan-Meier curve analysis
showed that the event rates were signiﬁcantly
different among these 5 groups (log-rank p < 0.0001)
(Figure 2C). Multivariable Cox hazard analysis adjusted
for age, dyslipidemia, BMI >25, and previous ACS
revealed that HRP(þ)/SS(þ) (HR: 17.24; p<0.0001) and
HRP(þ)/SS() (HR: 13.13; p < 0.0001) had signiﬁcantly
higher rates of ACS compared with no-plaque patients
(Table 3). The baseline model for the C-index included
age, male sex, hypertension, dyslipidemia, diabetes,
BMI >25 kg/m2, and previous ACS. As compared with
the baseline model (C-index 0.805), adding HRP
(0.870; p < 0.0001) and HRPþSS (0.874; p < 0.0001) to
the baseline model signiﬁcantly improved the C-index
(Figure 3). However, the baseline model plus SS did
not show improvement in C-index (0.818; p ¼ 0.071).
LESION-BASED ANALYSIS. Of the 88 patients with
events, ACS developed in 22 HRP(þ)/SS(þ) patients,
26 HRP(þ)/SS() patients, 14 HRP()/SS(þ) patients,
and 26 HRP()/SS() patients (Figure 1). In HRP(þ)/
SS(þ) patients, 3 ACS occurred at the SS but accom-
panying non-HRP, and 3 occurred at the lesion with
HRP but without SS. In HRP()/SS(þ), 1 ACS occurred
at a SS() lesion. Of 88 patients with ACS, 45 (51%)
patients developed ACS at HRP(þ) lesions and 43
(49%) patients at HRP() lesions. Eighteen (40%) of
45 HRP lesions developed ACS at 1 year and 31 (69%)
at 2 years. The period from CTA to ACS was signiﬁ-
cantly shorter for those developing events associated
with HRP(þ) lesions than for patients with ACS at
HRP() lesions (1.7  1.8 years vs. 3.4  2.4 years;
p ¼ 0.0005) (Online Figure 1A). SS at culprit lesions on
CTA was detected in 32 (36%) patients. There was no
signiﬁcant difference in the time interval from CTA to
ACS between the patients with culprit lesions of SS(þ)
and SS() (2.5  2.4 years vs. 2.6  2.2 years; p ¼ 0.80)
TABLE 2 Variables for ACS Development
Univariable Multivariable
HR (95% CI) p Value HR (95% CI) p Value
Age 1.02 (1.00–1.04) 0.1048 1.02 (1.00–1.04) 0.0974
Male 1.83 (1.10–2.26) 0.0200 1.04 (0.60–1.93) 0.8912
Hypertension 2.96 (1.81–5.12) <0.0001 1.12 (0.65–2.02) 0.6876
Dyslipidemia 4.63 (2.74–8.39) <0.0001 3.34 (1.89–6.32) <0.0001
Diabetes 1.72 (1.10–2.64) 0.0190 1.16 (0.73–1.80) 0.5246
Current smoking 1.58 (0.97–2.49) 0.0655
BMI >25 kg/m2 1.93 (1.26–2.94) 0.0026 1.72 (1.11–2.65) 0.0148
Previous ACS 4.10 (2.65–6.48) <0.0001 2.11 (1.33–3.42) 0.0014
No statin after CTA 0.27 (0.16–0.43) <0.0001
HRP 12.33 (8.11–18.86) <0.0001 8.24 (5.26–12.96) <0.0001
Stenosis $70% 3.27 (2.11–5.00) <.0001 1.61 (1.01–2.53) 0.0449
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
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341(Online Figure 1B). The numbers of patients with ACS
each year on the basis of culprit lesion characteristics
are shown in the Central Illustration. The cumulative
number of patients with ACS at HRP lesions was higher
in the ﬁrst 5 years; however, the number of ACS at
HRP() lesions became similar at 7 years.
SERIAL CTA ANALYSIS. Of the 449 patients who had
serial CTA available for comparative analysis, the
mean age was 65  11 years, and 85% were male
(Online Table 1). Median follow-up was 4.1 years, and
the median interval period from CTA-1 to CTA-2 was 1
year. Twenty-six patients were excluded from serial
CTA analysis because of intercurrent cardiac events
before CTA-2: 8 ACS and 18 elective revascularization
because of stable angina pectoris (SAP) (Figure 4A). Of
8 ACS, 7 had HRP on CTA-1 without SS, and 1 patientFIGURE 2 Cardiac Events on the Basis of CTA
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A total of 88 (2.8%) patients developed ACS during follow-up. Patients with HRP had a higher risk of events compared with patients without HRP (16.3% vs. 1.4%) (A),
as did patients with SS than did those without (5.5% vs. 2.1%) (B). (C) Patients were classiﬁed into 5 groups on the basis of plaque characteristics and luminal stenosis
[HRP(þ)/SS(þ); HRP(þ)/SS(); HRP()/SS(þ); HRP()/SS(); and no plaque]; event rates were 18.8%, 14.9%, 2.6%, 1.2%, and 0.6%, respectively. CTA ¼ computed
tomography angiography; other abbreviations as in Figure 1.
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TABLE 3 ACS Development per Plaque and Stenosis Characteristics
Group
ACS
n (%)
Unadjusted HR
(95% CI) p Value
Adjusted HR*
(95% CI) p Value
No plaque
(n ¼ 360)
2 (0.6) 1.00 Reference 1.00 Reference
HRP()/SS()
(n ¼ 1,962)
24 (1.2) 2.01 (0.60–12.53) 0.2937 1.31 (0.38–8.19) 0.7063
HRP()/SS(þ)
(n ¼ 542)
14 (2.6) 5.39 (1.50–34.38) 0.0071 2.89 (0.79–18.60) 0.1188
HRP(þ)/SS()
(n ¼ 177)
26 (14.9) 25.04 (7.48–155.47) <0.0001 13.13 (3.80–82.66) <0.0001
HRP(þ)/SS(þ)
(n ¼ 117)
22 (18.8) 38.98 (11.45–243.55) <0.0001 17.24 (4.87–109.47) <0.0001
*Adjusted for age, dyslipidemia, BMI >25 kg/m2, and previous ACS.
SS ¼ signiﬁcant stenosis $70%; other abbreviations as in Tables 1 and 2.
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342had neither HRP nor SS; all events occurred before
CTA-2. In 18 patients with SAP before CTA-2, 2 patients
were associated with HRP on CTA-1 and 16 were
without HRP on CTA-1; 5 patients had cardiac events
before CTA-2, and 13 patients underwent CTA-2 be-
cause of a cardiac event. Of 2 patients with HRP, 1 had
SS and the other did not have SS. Of 16 patients with
SAP without HRP, 1 patient had and 15 did not have
SS on CTA-1. After excluding 26 patients with cardiac
events before CTA-2, the remaining 423 patients
were analyzed for the usefulness of serial evaluation.
On CTA-1, HRP was observed in 70 of 449 (15.6%)
patients (Online Table 1). Of 423 patients whontal Value of CTA to Detect ACS
lse Positive Rate (1 - Specificity)
.2 0.4 0.6
No discrimination
C index (95% CI) P
Ref
<0.0001
<0.0001
0.071
0.805
(0.766-0.844)
0.870
(0.833-0.907)
0.818
(0.783-0.853)
0.874
(0.839-0.909)
Baseline model
Baseline model
plus HRP
Baseline model
plus SS
Baseline model
plus HRP+SS
0.8 1
for C-index included the following variables: age, male sex, hyper-
, diabetes, BMI >25 kg/m2, and previous ACS. Whereas adding HRP
(red) showed signiﬁcant improvement to the C-index beyond the
le), adding SS (blue) did not. AUC ¼ area under the curve; BMI ¼
¼ conﬁdence interval; other abbreviations as in Figures 1 and 2.underwent CTA-2, HRP was observed in 72 (17.0%)
(Figure 4A); 57 had HRP on both CTA-1 and CTA-2, and
15 patients with non-HRP on CTA-1 developed an HRP
on CTA-2. Four HRPs on CTA-1 became non-HRP
on CTA-2.
PP was observed in 56 (13.2%) patients (Figure 4A),
of which 15 (26.8%) had HRP on both CTA-1 and
CTA-2. Non-HRP on CTA-1 evolved to HRP on CTA-2
in 13 (23.2%) patients, and 28 (50%) non-HRP on
CTA-1 remained so upon CTA-2. In the PP group, the
vascular RI was signiﬁcantly greater on CTA-2 than
on CTA-1 (1.11  0.15 vs. 1.05  0.10; p < 0.0001).
BMI >25 kg/m2 (41.1 vs. 27.8%; p ¼ 0.04), and HRP at
CTA-1 (26.8 vs. 12.5 %; p ¼ 0.0047) were signiﬁcantly
more frequent in the PP(þ) group (Online Table 1).
ACS occurred in 8 (14.3%) of 56 patients in the PP(þ)
group and 1 (0.27%) of 367 in the PP() group
(Figure 4A). Of 8 patients with ACS in the PP(þ) group,
4 had HRP(þ) on both CTA-1 and CTA-2, 3 had HRP()
on CTA-1 but HRP(þ) on CTA-2, and 1 had HRP() on
both CTA-1 and CTA-2. Only 1 ACS occurred in the
PP() group with HRP() on both CTA-1 and CTA-2
in the 3-year period from CTA-2 to ACS. Kaplan-
Meier analysis revealed that patients with PP had a
signiﬁcantly higher incidence of ACS (log-rank
p < 0.0001) (Figure 4B). Multivariable Cox hazard
analysis (including age, BMI >25 kg/m2, previous ACS,
HRP on CTA-1, HRP on CTA-2, and PP) showed that
previous ACS (HR: 8.35; 95% CI: 1.06 to 209.55;
p ¼ 0.043) and PP (HR: 33.43: 95% CI: 4.13 to 78.03;
p ¼ 0.0006) were the only independent predictors of
ACS after CTA-2 (Table 4). Patients were classiﬁed
into 4 groups according to the combination of HRP
on CTA-1 and PP [HRP(þ)/PP(þ), HRP(þ)/PP(),
HRP()/PP(þ), HRP()/PP()]; the event rates were
26.7%, 0%, 9.8%, and 0.3%, respectively. In the
Kaplan-Meier analysis, the HRP(þ)/PP(þ) group pre-
sented with ACS most frequently (n ¼ 4 of 15; 27%;
p < 0.0001); the HRP()/PP(þ) group also had a rela-
tively high incidence of ACS (n ¼ 4 of 41; 10%).
Conversely, the HRP(þ)/PP() group (n ¼ 46) had no
cardiac event (Figure 4C). Multivariable Cox hazard
analysis adjusted for age, current smoking, and pre-
vious ACS showed that the HRP(þ)/PP(þ) group
(HR: 70.43; 95% CI: 8.99 to 1,500.74; p < 0.0001) and
HRP()/PP(þ) group (HR: 37.10; 95% CI: 5.41 to
730.20; p ¼ 0.0002) had a signiﬁcantly higher inci-
dence of ACS compared to HRP()/PP() group
(n ¼ 1 of 321; 0.3%) (Online Table 2, Online Figure 2).
DISCUSSION
The presence of CTA-based HRP was an independent
mid-term predictor of ACS, and all but 2 patients with
CENTRAL ILLUSTRATION Prediction of ACS by CTA
Motoyama, S. et al. J Am Coll Cardiol. 2015; 66(4):337–46.
HRP (+)
HRP (-)
HRP(+)
HRP(-)
HRP (+)
HRP(-)
Atherosclerosis is a diffuse disease, and the focus should not only be on chasing high-risk plaques (HRP), but also on prevention and treatment of
atherosclerotic disease. Low attenuation (#30 Hounsﬁeld units) and/or positively remodeled plaques identiﬁed on computed tomography angiography
(CTA) are considered HRP that are known to be associated with adverse short-term outcomes. The current study looked at the mid-term outcomes.
Although the event rate (left) was substantially higher for HRP (red) as compared with non-HRP (green), the total number of events arising from HRP and
non-HRP at the follow-up of 3.9  2.4 years (range 1 to 10.5 years) was essentially the same (right). In the study of 3,158 subjects, 294 (9.3%) had HRP(þ);
2,864 (90.7%) did not show HRP [HRP()]. On follow-up, 48 (16.3%) of the 294 HRP-carrying and 40 (1.4%) of 2,864 non–HRP-carrying subjects
developed acute events. Although the outcomes were 10-fold worse in HRP(þ) as compared with HRP(), because the number of subjects with HRP(þ) was
10-fold lower, equal numbers of acute events were observed in the HRP(þ) and HRP() patients. Serial CTA examinations (Figure 4) revealed plaque
progression and evolution from non-HRP to HRP en route acute coronary event. The focus, therefore, should be on the diffuse process of atherosclerosis.
The inset in the left panel shows the difference between event rate from HRP and non-HRP by magnifying the y-axis scale.
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343no plaques were free from ACS. However, non-HRP
lesions also developed ACS, and serial CTA analysis
revealed the plaques that progressed over time on a
volumetric basis and evolved from non-HRP to HRP
were the ones more likely to result in ACS. We had
previously reported that CTA-veriﬁed HRP had a
higher risk of developing ACS over a mean follow-up
of 2 years in 1,059 patients; ACS developed in 15% of
HRP(þ) patients and in 0.5% of HRP() patients, but
did not develop in patients without any plaques (10).
The present study demonstrated that HRP con-
tinued to be an independent predictor of ACS in mid-
term follow-up in 3,158 patients (mean follow-up
3.9  2.4 years; ranging from 1 to 10.5 years); ACS fre-
quency was 16% in HRP(þ) patients versus 1.6% in
HRP() patients at baseline CTA assessment. The
event rate of ACS in patientswithout HRPwas higher in
the current study compared with that reported in the
previous study with a 2-year follow-up. The period
from CTA to ACS was signiﬁcantly shorter for those
developing events associated with HRP(þ) lesions
than for patients with ACS at HRP() lesions (1.7  1.8
years vs. 3.4  2.4 years; p ¼ 0.0005). Because fewer
than 10% of patients had HRP, the cumulative number
of ACS arising from HRP lesions, although larger in theﬁrst 5 years, was almost matched by the number of ACS
arising from the more numerous HRP() lesions.
SS, in addition to HRP, was also an independent
predictor of ACS. Earlier reports have discussed the
prognostic value of CTA-veriﬁed stenosis for risk
stratiﬁcation (5–7), and a meta-analysis of 18 studies
comprising 9,592 patients reported that the risk of
adverse cardiac events was associated with the extent
and severity of underlying CAD (6). In the present
study, patients with signiﬁcantly stenotic HRP had
higher event rates compared with the non-stenotic
HRP or stenotic non-HRP patients; very low event
rates were observed in those with non-HRP, non-
stenotic plaques or no plaques.
The PROSPECT (Providing Regional Observations to
Study Predictors of Events in the Coronary Tree) reg-
istry revealed similar data derived from IVUS, with the
best predictive values attributed to larger plaque
burden (>70%; HR: 5.03; 95% CI: 2.51 to 10.11), pres-
ence of thin-cap ﬁbroatheroma (TCFA) (HR: 3.35; 95%
CI: 1.77 to 6.36), and lower minimal luminal areas
(<4.0mm2; HR: 3.21; 95%CI: 1.61 to 6.42) for the lesions
likely to result in an acute event over the 3.4-year
follow-up (8). A related study provided shorter serial
imaging data but with results similar to those of the
FIGURE 4 Serial CTA Analysis and Cardiac Events
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(A) The relationship between HRP (CTA-1 and -2), PP (CTA-2), and cardiac events is shown. On CTA-2, ACS occurred in 7 HRP(þ) and 2 HRP()
patients. Of these 9 patients, 8 patients were PP(þ) and 1 PP(). No HRP(þ)/PP() patients on CTA-1 developed ACS. (B) Presence of PP
produced a signiﬁcantly higher incidence of ACS (14.3% vs. 0.3%). (C)When patients were classiﬁed according to the presence/absence of HRP
on CTA-1 and PP on CTA-2, HRP(þ)/PP(þ) presented with the most frequent ACS (27%; log-rank p < 0.0001) . Conversely, the HRP(þ)/PP()
group had no cardiac events. PP ¼ plaque progression; SAP ¼ stable angina pectoris; other abbreviations as in Figures 1 and 2.
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344current study (15). In this IVUS study, plaques charac-
terized as pathological intimal thickening (PIT)
evolved into TCFA or thick-cap ﬁbroatheroma (ThCFA)
in 10% and 20% of patients over 12 months; 70% of PIT
remained unchanged. Conversely, 75% of TCFA stabi-
lized over the next year, and 5% of ThCFA developed
high-risk features. Because fewer than 10% of initial
lesions were reported as TCFA, the net number of new
TCFA producedwas similar to the number of TCFA that
stabilized over time (16). None of the plaque charac-
teristics, however, could predict the likelihood of
developing TCFA from PIT or ThCFA, or its stabiliza-
tion. This observational study suggested that athero-
sclerosis is a diffuse and dynamic process with plaque
undergoing biological remodeling and compositional
alterations. A recent optical coherence tomography
study of 3-vessel imaging revealed that multipleplaques concurrently existed across the coronary tree
at different stages of maturation (17).
The present exploration reveals that because of the
much larger number of HRP() patients, the total
number of ACS arising from non-HRP at the end of
follow-up is similar to that of HRP(þ) lesions. As
detected by serial CTA, PP addresses the development
of ACS from non-HRP, at least partially, and emerges
as an independent predictor of cardiac events. In the
patients with serial CTA, although HRP on CTA-1 was
an independent predictor of subsequent cardiac
events (15.7% of HRP patients resulted in ACS), 5 of 9
(56%) of ACS developed from originally HRP() plaque
on CTA-1. Plaque progression at CTA-2 was also an
independent predictor of ACS, with adverse events
occurring in 8 (14.3%) of 56 patients in the PP(þ) group
and 1 (0.3%) of 367 in the PP() group. Of the 8 ACS
TABLE 4 Cardiac Events After CTA-2
Univariable Multivariable
HR (95% CI) p Value HR (95% CI) p Value
Age 0.99 (0.94–1.06) 0.85 1.00 (0.95–1.08) 0.87
Male 1.32 (0.24–24.55) 0.78
Hypertension 1.59 (0.39–10.70) 0.54
Diabetes 1.13 (0.24–4.27) 0.87
Dyslipidemia 0.86 (0.22–4.06) 0.83
BMI >25 kg/m2 5.58 (1.46–26.52) 0.012 3.27 (0.66–24.42) 0.15
Current smoking 2.35 (0.62–9.51) 0.20
Previous ACS 6.26 (1.15–116.32) 0.032 8.35 (1.06–209.55) 0.043
Statin use 1.11 (0.27–7.44) 0.90
Chest pain at CTA-2 3.09 (0.65–11.73) 0.14
HRP at CTA-1 4.40 (1.08–16.67) 0.039 0.85 (0.07–9.01) 0.89
HRP at CTA-2 9.07 (2.38–43.11) 0.0014 2.18 (0.20–27.78) 0.51
Plaque progression 61.32 (11.24–1,137.73) <0.0001 33.43 (4.13–78.03) 0.0006
Abbreviations as in Tables 1 and 2.
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345patients with PP at CTA-2, HRP was observed in
7 patients on CTA-2; 4 patients had HRP both on CTA-1
and CTA2, and 3 HRP() on CTA-1 developed HRP(þ)
on CTA-2. These results indicate that plaques without
high-risk features may evolve to HRP, eventually
leading to ACS. On the other hand, patients with HRP
on CTA-1, but without PP by CTA-2, remained free of
untoward events. These results suggest that serial
plaque evaluation may help restratify the risk of
cardiac events beyond a single evaluation.
On the basis of the 2010 Appropriateness Use
Criteria for Cardiac Computed Tomography, the
appropriateness of CTA for asymptomatic high-risk
patients with unknown CAD is uncertain (18). Addi-
tionally, guidelines have not recommended treat-
ment or management of HRP on the basis of CTA; the
2010 Expert Consensus Document on coronary CTA
ruled that documentation of noncalciﬁed coronary
plaques, atherosclerotic burden, and vulnerable pla-
ques provided uncertain clinical utility (19). As evi-
dence unfolds with regard to documented HRP on
CTA, expert consensus statements may require
updated guidance on directed management of these
patients. Moreover, clinical trial evidence would
deﬁnitively inform evidentiary standards on
guideline-directed care. The current study demon-
strated that dyslipidemia, BMI >25 kg/m2, previous
ACS, HRP, and severe stenosis were independent
predictors of ACS, and BMI >25 kg/m2 and HRP were
associated with PP. Also, patients with a history of
ACS have been reported to show higher coronary
event rates than those without (20–22). On the basis
of these results, patients with HRP or previous ACS
might be candidates for serial CTA. However, radiation
dose, use of contrast media, and cost effectiveness
would need to be considered. The appropriate number
and frequency of serial scans remains undetermined.
The current exploration combined with evidence from
previous reports (16) underscores that although sig-
niﬁcantadvanceshavebeenmade inunderstandingthe
biology of HRP, our focus must remain on the entire
atherosclerotic process and prevention of diffuse dis-
ease. Our data support the statement that seeking in-
dividual plaquesmay not provide the ultimate answer.
STUDY LIMITATIONS. First, this is a retrospective
cohort study. Of 4,423 patients who underwent CTA,
590 (13%) were excluded because of the lack of 1-year
follow-up. Second, individual physicians determined
indications for repeat CTA, making selection bias a
distinct possibility; thus, the data presented here
should only be considered hypothesis generating.
Third, in assessing serial CTA, differences in imaging
platforms from 16- and 64- to 320-slice scanners could
have affected image quality and comparability.However, all CTA images were interpreted by 2
cardiologists blinded to the patient’s clinical infor-
mation. Fourth, it is difﬁcult to evaluate the lumen
stenosis and the presence of HRP in calciﬁed lesions,
and in such areas, luminal stenoses are likely to
be overestimated and HRP underestimated. Finally,
because we focused on the plaque characteristics
associated with ACS, we included only those patients
whose culprit plaques could be identiﬁed. However,
the plaque characteristics of the patients who died
without having invasive coronary angiography and
of those with ACS who did not have the culprit lesion
identiﬁed might have affected the considerations
of the likelihood of ACS on the basis of CTA plaque
characteristics. Thus, the patients without invasive
coronary angiography could have added to our current
understanding of HRP and incident ACS. Importantly,
a prognostic analysis including these patients in a Cox
model did not alter our presented ﬁndings.
CONCLUSIONS
CTA-veriﬁed HRP is an independent predictor of ACS
over a mid-term follow-up of 3.9  2.4 years. How-
ever, the cumulative number of ACS patients with
HRP() is similar to patients with HRP(þ). In addition
to HRP, plaque progression detected by serial CTA is
an independent predictor of ACS.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: High-risk
coronary plaques, characterized by low attenuation and
evidence of positive remodeling on coronary computed
tomographic angiography, are associated with develop-
ment of acute coronary syndromes.
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: Patients with high-risk plaque
should receive aggressive risk factor management,
regardless of the severity of arterial obstruction.
TRANSLATIONAL OUTLOOK: Randomized trials are
needed to compare the clinical outcomes associated with
pharmacological and mechanical interventions in patients
with nonobstructive, high-risk coronary plaque
morphology.
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